Beligas Pharmaceuticals | Beligas Pharma

Etho® – Testosterone 300mg (1 vial)

$80.00

Active ingredients: Testosterone Enanthate
 Carrier Oil: MCT Oil (no EO)
 Pharmacological Category: Androgenic hormone
 Composition: Every 1 mL contains 300 mg of Testosterone Enanthate
 Active life:14 days
 Detection time:3 months
 Anabolic/ Androgen ratio: 100/100
Category:

Mechanism of Action 


Testosterone (Etho® – Testosterone 300mg) influences the body through two primary pathways: activating androgen receptors (either directly or after conversion to DHT) and converting into estradiol, which then interacts with estrogen receptors. Once free testosterone enters the cytoplasm of target cells, it either binds to the androgen receptor or is converted into 5-alpha-dihydrotestosterone (DHT) by the enzyme 5-alpha-reductase. DHT attaches to the same receptor with a stronger affinity, giving it significantly higher androgenic activity than testosterone itself. After binding, the testosterone-receptor or DHT-receptor complex changes shape, moves into the nucleus, and attaches to specific DNA sequences known as hormone response elements. This interaction influences gene transcription and leads to androgenic effects. Androgen receptors are found throughout the body, and both men and women react similarly at comparable hormone levels. Differences in testosterone exposure during fetal development, puberty, and adulthood largely explain biological distinctions between the sexes.

Indications


Men: Testosterone Enanthate is prescribed when the body does not produce sufficient natural testosterone. This includes primary hypogonadism caused by conditions such as undescended testes, torsion, orchitis, vanishing testis syndrome, or surgical removal of the testes. Long-term therapy may be required to sustain masculine characteristics in men who lose testosterone production after puberty. It can also be used to help initiate puberty in selected males with delayed but non-pathological puberty, after other causes are ruled out. Treatment should be conservative, and patients must be monitored for effects on bone development with periodic hand and wrist X-rays.
Women: Testosterone Enanthate may be used as supportive therapy in postmenopausal women with progressing, inoperable metastatic breast cancer. The goal is to counteract estrogen activity. Similar approaches include adrenalectomy, hypophysectomy, or anti-estrogen treatment. It has also been used in certain premenopausal cases where the tumor responds to hormonal changes. Decisions regarding therapy must be made by an experienced oncologist. It has occasionally been used to manage pain and breast engorgement after childbirth.

Contraindications 


This medication is not suitable for men with known or suspected prostate cancer or male breast cancer. It is also contraindicated in women who are pregnant or may become pregnant. Exposure to androgens during pregnancy can cause virilization of a female fetus, including changes in genital development. The severity depends on dosage and timing, particularly during the first trimester. If pregnancy occurs during treatment, the patient should be informed of the possible risks.

Side Effects:


Equipoise is usually tolerated well, but potential effects can include acne, increased hair growth, and mood changes. Any concerning symptoms should be monitored and discussed with a healthcare professional.

Drug Interactions:


Using androgens together with oxyphenbutazone may increase levels of the latter. In individuals with diabetes, testosterone may lower blood glucose and decrease insulin or oral antidiabetic requirements.

Dosage:


Testosterone Enanthate is given by intramuscular injection only—never intravenously. Injections should be delivered deeply into the gluteal muscle. Dosages vary depending on the patient’s condition, age, and treatment goals. Replacement therapy for men with testosterone deficiency typically ranges between 50–400 mg every 2–4 weeks, adjusted based on response and side effects. Higher doses may be used by medical professionals when necessary. For non-medical enhancement, weekly amounts of 300–600 mg are commonly used, though such use should be medically supervised.
For women with inoperable breast cancer, a dose of 50–100 mg weekly may be recommended as part of palliative therapy.

Injection Technique & Site Care:

  • Warm the vial in your hands before injecting

  • Use a clean 25G–27G needle and syringe

  • Inject slowly into the muscle

  • Gently massage the area afterward

  • Rotate injection locations to avoid irritation

  • Do not inject into swollen or previously affected sites

  • Keep the vial upright and avoid shaking

Storage:


Store at room temperature in a dry, dark place. Do not refrigerate. Keep away from children.

Regulatory Compliance:

  • Manufactured in accordance with applicable regulatory standards

  • Produced under certified Good Manufacturing Practices (GMP)

Safety Information:

  • In case of overdose, seek medical help immediately

  • Report any unexpected or concerning reactions to your healthcare provider

  • This medication requires a prescription and should be used only under qualified medical supervision

Related products